Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of GP Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Single-arm, Phase 2 Trial

Next Previous
Trial Profile

Efficacy and Safety of GP Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Single-arm, Phase 2 Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Antineoplastics; Cisplatin; Gemcitabine; Immunotherapies
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 07 Jun 2022 Results assessing efficacy and safety of neoadjuvant treatment with tislelizumab in previously untreated locoregionally advanced nasopharyngeal carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
  • 15 Apr 2021 Status changed from not yet recruiting to recruiting.
  • 07 Apr 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top